{
    "nct_id": "NCT05647122",
    "official_title": "A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy ≥ 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n\nAdditional Inclusion Criteria for Module 1:\n\n• Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC.\n\nAdditional Inclusion Criteria for Module 2:\n\n• Histologically or cytologically confirmed metastatic NSCLC EGFRmut.\n\nAdditional Inclusion Criteria for Module 3:\n\n• Histologically or cytologically confirmed metastatic CRC.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Spinal cord compression or a history of leptomeningeal carcinomatosis.\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment.\n* Participants with cardiac comorbidities as defined in the study protocol",
    "miscellaneous_criteria": "Key"
}